Guggenheim downgraded Adaptimmune (ADAP) to Neutral from Buy.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune downgraded to Neutral from Buy at H.C. Wainwright
- Adaptimmune Sells Cell Therapy Assets to US WorldMeds
- Adaptimmune Settles Litigation with M.D. Anderson Cancer Center
- General Mills upgraded, Trade Desk downgraded: Wall Street’s top analyst calls
- Mizuho downgrades Adaptimmune to Neutral on solvency concerns